Anadrol vs RAD-140
FDA Approved vs Emerging
avoid Mechanism-based · 53% Both Anadrol and RAD-140 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Anadrol RAD-140
Weight 332.48 Da 393.83 Da
Half-life ~8-9 hours ~60 hours
Type 17-alpha alkylated anabolic steroid (C21H32O3) Nonsteroidal selective androgen receptor modulator (C20H16ClN5O2)
Key Benefits
Anadrol
01 Rapid and dramatic increases in muscle mass and bodyweight
02 Exceptional strength gains, often noticeable within the first week
03 Potent stimulation of erythropoietin and red blood cell production
04 Increased appetite and nutrient partitioning in some users
05 Improved recovery between training sessions
06 Full, round muscle appearance due to intramuscular water and glycogen retention
07 FDA-approved treatment for various forms of anemia
RAD-140
01 Potent anabolic activity in muscle tissue with high oral bioavailability
02 Tissue-selective action sparing the prostate and other androgen-sensitive organs
03 No aromatization to estrogen (no estrogen-related side effects such as water retention or gynecomastia)
04 No conversion to DHT (reduced risk of hair loss and prostate stimulation compared to testosterone)
05 Long half-life (~60 hours) permitting convenient once-daily oral dosing
06 Neuroprotective properties observed in preclinical models
07 Increased lean body mass and reduced fat mass in preclinical studies
Side Effects
Anadrol
Significant water retention and bloating (estrogenic, not aromatase-mediated)
Elevated blood pressure (fluid volume and RBC increase)
Severe liver stress and elevated liver enzymes (AST/ALT)
Back pumps and lower back pain during exercise
Headaches (often blood pressure-related)
Appetite suppression (paradoxical for a mass-building compound)
Lethargy and fatigue (hepatic strain-related)
Acne and oily skin
Suppression of natural testosterone production
RAD-140
Testosterone suppression (dose-dependent, occurs in virtually all users by week 4-6)
Liver enzyme elevation (ALT, AST increases reported in clinical and anecdotal data)
Hair shedding (temporary, typically resolves after discontinuation)
Headaches (most common in the first 1-2 weeks, often transient)
Nausea (mild, usually with initial doses or on an empty stomach)
Lipid disruption (HDL suppression, LDL elevation)
Mild insomnia or sleep disturbance
Reduced libido and mood changes related to testosterone suppression
Contraindications
Pre-existing liver disease or significantly elevated liver enzymes
Prostate cancer or breast cancer in males
Nephrotic phase of nephritis
Hypercalcemia (Anadrol can exacerbate calcium levels)
Pregnancy (Category X - causes virilization of the female fetus)
Known hypersensitivity to oxymetholone
Concurrent use of other 17-alpha alkylated oral steroids (compounded liver toxicity)
Pre-existing liver disease or elevated liver enzymes at baseline
Hormone-sensitive cancers (prostate cancer, certain breast cancers not being treated under clinical supervision)
Pregnancy or potential pregnancy (teratogenic risk from androgen receptor agonism)
Breastfeeding
Age under 25 (incomplete endocrine system maturation and higher risk of HPG axis disruption)
Concurrent use of hepatotoxic medications without medical supervision
Known cardiovascular disease (insufficient safety data for this population)
Research Evidence
Anadrol RAD-140
Status FDA Approved Emerging
References 5 studies 5 studies
Latest 2018 July 2020
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.